<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935830</url>
  </required_header>
  <id_info>
    <org_study_id>201307040</org_study_id>
    <nct_id>NCT01935830</nct_id>
  </id_info>
  <brief_title>LAAM-HAART PET Imaging</brief_title>
  <official_title>Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the antiretroviral drugs efavirenz&#xD;
      and ritonavir on human brain LAAM disposition in vivo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral [11C]LAAM distribution volume</measure>
    <time_frame>approximately 3 months</time_frame>
    <description>Blood tests, MRI and PET data analysis and interpretation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LAAM arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)&#xD;
Efavirenz, oral capsules, 600 mg&#xD;
Ritonavir, oral capsules, 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[11c] LAAM</intervention_name>
    <description>intravenous administration of 15-20 mCi of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
    <other_name>Sustiva, Atripla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
        Each subject must meet all of the following criteria:&#xD;
&#xD;
          1. Male or non-pregnant female volunteer, 18-50 yr old&#xD;
&#xD;
          2. Good general health with no known major medical conditions&#xD;
&#xD;
          3. BMI &lt; 33&#xD;
&#xD;
          4. Provide informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects will not be enrolled if any of the following criteria exist:&#xD;
&#xD;
          1. Known history of liver or kidney disease&#xD;
&#xD;
          2. History of major medical conditions&#xD;
&#xD;
          3. HIV seropositive&#xD;
&#xD;
          4. Fasting blood glucose &gt; 110 mg/dl (because HAART can cause glucose intolerance)&#xD;
&#xD;
          5. Family history of type 2 diabetes&#xD;
&#xD;
          6. Use of prescription or non prescription medications, herbals or foods known to be&#xD;
             metabolized by or altering P-glycoprotein or CYP3A (hormonal birth control medications&#xD;
             are acceptable if alternative means of contraception are used)&#xD;
&#xD;
          7. Females who are pregnant or nursing&#xD;
&#xD;
          8. Females taking hormonal contraceptives who are unwilling to use alternative means of&#xD;
             contraception&#xD;
&#xD;
          9. Contraindications to MRI (e.g., metal implants or splinters in the body; a worn or&#xD;
             implanted medical device, such as a pacemaker or drug pump; inability to lie flat for&#xD;
             up to one hour; claustrophobia) or contraindications to PET scanning (e.g., inability&#xD;
             to lie flat for up to one hour, claustrophobia, current&#xD;
&#xD;
         10. Current or recent (within 12 months prior to screening) participation in research&#xD;
             studies involving radiation exposure such that the total research-related radiation&#xD;
             dose to the subject in any given year would exceed the limits set forth in the US Code&#xD;
             of Federal Regulations (CFR) Title 21 Section 361.1&#xD;
             (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1))&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan D Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET Imaging</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Ritonavior [11C] LAAM</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

